NICE U-turn puts Janssen's Zytiga ahead of Sanofi's Jevtana in prostate cancer
This article was originally published in Scrip
A revised patient access scheme and more information about the patients likely to benefit from Janssen Cilag's Zytiga (abiraterone) have persuaded NICE, the health technology appraisal body for England and Wales, to change its mind and recommend the drug for castration-resistant metastatic prostate cancer patients after one round of treatment with docetaxel.
You may also be interested in...
Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.
With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.